New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →What's hot!
View all perspectives
What's Hot
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented at EULAR 2026.
Watch video →
‘Strong’ Treatment Predictions in Inflammatory Myositis
Dr. Janet Pope, reports on abstracts POS0264 and OP0166, presented at the 2026 EULAR meeting in London.
Watch video →
Imaging in Subclinical Psoriatic Arthritis
Dr. Antoni Chan discusses abstract OP068 presented at EULAR 2026.
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
Nelly ZIADE 🍀 Nellziade
2 months 1 week ago
What’s in the pipeline for #psoriatic_arthritis treatment?
A special focus on Tyk2 inhibitors
WIN session at #EULAR2026
@RheumNow https://t.co/dDJtmdx9xU
Aurelie Najm AurelieRheumo
2 months 1 week ago
What is new in PsA?
Dennis McGonagle's take at #EULAR2026
-a strong year for discovery in mechanisms of transition from PSO to PsA
-publication of the first single cell atlas Enthesis
-Better understanding of VTE mechanisms in JAKi in PsA
-clinical aspects of Axial involvement https://t.co/v9cfn1y4fH
sheila RHEUMarampa
2 months 1 week ago
Pts with AIIRD carry a high risk & burden of infection due to immune dysregulation, comorbids, GC/DMaRD use.
As a rheumatologist, do you vaccinate your patients?
#EULAR2026 @RheumNow
Dr. John Cush RheumNow
2 months 1 week ago
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.
sheila RHEUMarampa
2 months 1 week ago
Prof. Pedro Machado shares this important slide on a quick guide to #vaccination in patients w/ RMDs highlighting which vaccines are universally indicated, accdg to epidemiologic risk and w/ CIs.
#EULAR2026 @RheumNow https://t.co/JmTSC1uaph
sheila RHEUMarampa
2 months 1 week ago
#Vaccination in Rheum
📍Hold MTX 1-2wks post vax
📍For Bcell depleters, timing is based on B-cell repop’n kinetics, not fixed calendar intervals.
THM: Assess vax need at dx, vax w/o delay
#EULAR2026 @RheumNow https://t.co/6ptl8gyBLR
Md Yuzaiful Md Yusof Yuz6Yusof
2 months 1 week ago
#EULAR2026 POS0438 In Part A (Phase II) RCT of Cutaneous #lupus, Litifilimab, a BDCA2 mAb improved CLASI-A vs PBO at Week 16.
-Improvement as early as Week 4
-Low viral infections. Common AE: nasopharyngitis & headache.
-Interested to see results of Part B (phase III) @RheumNow https://t.co/2zzHd9NgBi
Md Yuzaiful Md Yusof Yuz6Yusof
2 months 1 week ago
#EULAR2026 Still undecided which session to attend? Please find my Conference Preview in the field of #SLE #lupus #biologics #targetedtherapy @RheumNow 😃
https://t.co/0m2p8mEgCQ https://t.co/C3xa5rPp9q
Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed with chronic immunosuppression.
We are in a transformative era in SLE which generates excitement to both physicians and people living with lupus. We now have four licensed biologics/targeted therapies (i.e., belimumab, voclosporin and obinutuzumab for active lupus nephritis, and belimumab and anifrolumab for active non-renal SLE). Moreover, many other agents with different mode of action and administration are in late phase trials. This article previews some data being
Nelly ZIADE 🍀 Nellziade
2 months 1 week ago
#EULAR2026 General Assembly is ON!
Record-breaking 5'705 abstracts from 102 countries
187 scientific sessions ahead
@rheumnow https://t.co/0kAqND11L7
Dr. John Cush RheumNow
2 months 1 week ago
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.
A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology holds its inaugural meeting. The launch marks an important step for a field that has been visible in clinical practice, but less visible in professional
Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.
